Starboard has approached two former Pfizer executives, Ian Read and Frank D’Amelio, to assist in its efforts, and they have ...

After Kaléo unveiled a “redesign” of the in-office commercial team for its EpiPen rival Auvi-Q at the start of the month, the ...

On 9 September the US House of Representatives passed the draft of the Biosecure Act, which aims to prohibit US pharma ...

Gilead Merger AstraZeneca, the UK’s largest drugmaker valued at $140bn, has reportedly contacted Gilead Sciences, an American ...

Here is the complete list of stocks exiting their IPO lock-in period between October 8, 2024, and December 31, 2024 ...

Mylan Pharmaceuticals Inc and Novo Nordisk, the original patent holder for Ozempic, have reached a settlement in the US ...

According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.

Natco Pharma rose 3.39% to Rs 1400.60 after the company announced a settlement in the U.S. patent litigation for generic Ozempic.

Kirk Spano and Bhavneesh Sharma talk biotech, pharma, and why complete response letters are a good contrarian buying ...

Mylan and Novo Nordisk have reached a confidential settlement over the generic version of Ozempic, with Natco Pharma holding ...

Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...

AstraZeneca Plc is licensing a drug from China’s CSPC Pharmaceutical Group Ltd that it hopes will treat high cholesterol, as ...